The S&P/ASX Small Ordinaries Index continued its strong run, climbing 2.28% on Friday to close at 3,501.80 and gaining 2.19% over the past five trading days, reflecting renewed investor appetite for growth-oriented small-cap stocks.
This morning, several ASX-listed companies have announced major financing, clinical, commercial and leadership developments aimed at supporting future growth. You can reads about the following and more throughout the day.
Greatland secures $500 million debt facility
Greatland Resources Ltd (AIM:GGP, OTC:GRLGF, FRA:G8G, ASX:GGP) has executed a $500 million corporate debt facility agreement with a syndicate of major lenders comprising ANZ, ING, HSBC, NAB and Westpac.
The agreement formalises the binding commitment letter announced in December 2025, with terms remaining broadly unchanged, including the absence of any mandatory hedging requirements, providing the company with significant financial flexibility as it advances its growth plans.
Imugene reports broad cancer responses
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) presented new Phase 1b data for its azer-cel cell therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
The company reported treatment responses across six different blood cancer subtypes in patients who had not previously received CAR-T therapy, adding to the growing body of evidence supporting the therapy's potential across a range of haematological cancers.
ReNerve expands into Greater Bay Area
ReNerve Ltd (ASX:RNV) announced a partnership with Swedish Trading Company Limited (STC) to commercialise its NervAlign products across Hong Kong, Macau and China's Greater Bay Area.
The agreement follows recently expanded product approvals in the region and is expected to strengthen the company's position in key Asian markets focused on peripheral nerve injury repair.
FortifAI appoints Silicon Valley veteran as CEO
FortifAI Ltd (ASX:FTI) has appointed technology industry veteran Kelly Herrell as chief executive officer of both FortifAI and its AI infrastructure subsidiary Nol8.
Herrell brings more than three decades of experience scaling high-growth technology companies, having held senior roles at businesses that collectively generated more than US$12 billion in merger, acquisition and IPO value, including CacheFlow and Cobalt Networks.
The appointment comes as FortifAI seeks to expand its artificial intelligence infrastructure capabilities and commercial reach.
Memphasys lands first South-East Asian distribution deal
Memphasys Ltd (ASX:MEM) has secured an exclusive commercialisation agreement with TMSC Viet Nam Medical Technology Company Limited for the sale and distribution of its Felix™ System in Vietnam.
The deal marks Memphasys' first commercial partnership in South-East Asia and supports the company's strategy of broadening its global distribution network. Vietnam's IVF market was estimated at around US$141 million in 2023 and is forecast to exceed US$200 million by 2029, driven by rising infertility rates, increased healthcare investment and growing demand for advanced fertility services.